Advantech Capital
China smart text processing start-up raises $92m
Data Grand, a China-based specialist in text recognition and processing robotics, has raised CNY 580m （USD 92m）in Series C round featuring China Merchants Securities, CITIC Securities, GF Securities, and China Securities.
China gene therapy start-up Cure Genetics raises $60m
Advantech Capital has led a USD 60m Series B for Suzhou-based biotech player Cure Genetics. Other investors include Oriza Holdings, Blue Ocean Private Equity, and Qiming Venture Partners.
China secondhand goods platform Zhuanzhuan raises $100m
Zhuanzhuan, a used goods trading platform and subsidiary of 58.com, China’s largest online classifieds marketplace, has raised a $100 million round led by electronics giant Xiaomi.
China mRNA specialist Stemirna gets $200m in funding
Stemirna Therapeutics, which claims to be the first biotech company to bring an mRNA therapeutics and nanomedicine platform to China, has raised $200 million in funding.
China's Zhihu completes $522m IPO, endures volatile debut
Chinese question-and-answer platform Zhihu endured a difficult New York Stock Exchange debut, closing at a 10.5% discount to its IPO price on a day when US-listed Chinese stocks fluctuated wildly.
China's Connect Biopharma gains 8% on debut after $191m US IPO
Connect Biopharma, a China-headquartered drug developer specializing in treatments for T cell-driven inflammatory diseases, gained 8.8% on debut following a $191.3 million US IPO.
China mobile charging business targets US listing
Energy Monster, China’s largest mobile device charging service provider by gross revenue, has filed for a US IPO.
PE-backed Harbour BioMed raises $221m in Hong Kong IPO
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.
China's InventisBio secures $147m Series D
GL Ventures, the China venture capital arm of Hillhouse Capital, has led a $147 million Series D round for Shanghai-based biotech developer InventisBio.
China's Alphamab Oncology gets $60m Series B
Chinese biopharmaceutical developer Alphamab Oncology has completed a $60 million Series B round led by US and UK-based investor Hudson Bay Capital Management.
Cancer drug developer Tot Biopharm files for HK IPO
Tot Biopharm, a private equity-backed Chinese cancer drug developer, has filed for a Hong Kong IPO under rules that allow for listings by pre-revenue biotech companies.
China's Bitmain pulls plug on Hong Kong IPO
Bitmain, a private equity-backed Chinese business that manufactures chips for Bitcoin mining, has allowed its application for a Hong Kong IPO to lapse.
Advantech, CMBI lead Series C for China's InventisBio
Advantech Capital and CMB International, an investment unit of China Merchants Bank, have led a $70 million Series C funding round for InventisBio, a Chinese clinical stage biotech company.
Advantech leads $55m round for China biotech player
Advantech Capital has led a $55 million Series B funding round for China’s Connect Biopharmaceuticals with support from Qiming Venture Partners.
China's Alphamab gets $100m Series A
China’s Alphamab Oncology has completed a $100 million Series A funding round from a group of investors including PAG Growth Capital, Advantech Capital, and OrbiMed.
PE-backed Chinese crypto player set for Hong Kong IPO
Bitmain, a five-year-old Chinese company that is the dominant global player in manufacturing chips for bitcoin mining, with revenues ballooning nearly tenfold to $2.5 billion last year, has filed for a Hong Kong IPO.
China's Qutoutiao soars on debut after $84m US IPO
Chinese news aggregator app Qutoutiao raised $84 million in a downsized US IPO – continuing a recent trend among Chinese tech start-ups – but then saw its stock price more than double on the first day of trading.
GIC leads $85m Series B for China's Harbour BioMed
Harbour BioMed, a China-based biopharmaceutical company focused on treatments for cancer and autoimmune disorders, has raised an $85 million Series B round led by Singapore’s GIC Private.
Chinese news aggregator Qutoutiao preps for US offering
Qutoutiao, a Chinese news aggregator app that seeks to differentiate itself from market leader Jinri Toutiao by focusing on entertainment-oriented content, has announced plans to list in the US.
VCs in $47m round for Chinese AI medical imaging firm
Beijing Infervision, a Chinese company that develops medical imaging technology empowered by artificial intelligence (AI), has raised RMB300 million ($47 million) in funding from investors including Xianghe Capital.
Tencent leads $200m round for China’s Qutoutiao
Tencent Holdings has led a Series B round worth more than $200 million for Qutoutiao, a Chinese mobile news reading app. The round gives the company a post-money valuation of $1.6 billion.
Advantech, Redview target $1.5b for China deals
Advantech Capital and Redview Capital – parallel entities formed following the restructuring of Chinese GP New Horizon Capital – are seeking a combined $1.5 billion for their latest funds.